Immunomodulation by intravenous omega-3 fatty acid treatment in older subjects hospitalized for COVID-19: a single-blind randomized controlled trial
View ORCID ProfileHildur Arnardottir, View ORCID ProfileSven-Christian Pawelzik, View ORCID ProfilePhilip Sarajlic, View ORCID ProfileAlessandro Quaranta, View ORCID ProfileJohan Kolmert, View ORCID ProfileDorota Religa, View ORCID ProfileCraig E. Wheelock, View ORCID ProfileMagnus Bäck
doi: https://doi.org/10.1101/2021.12.27.21268264
Hildur Arnardottir
1Department of Medicine, Karolinska Institutet, Theme Heart, Vessels, and Neuro, Karolinska University Hospital, Stockholm, Sweden
PhDSven-Christian Pawelzik
1Department of Medicine, Karolinska Institutet, Theme Heart, Vessels, and Neuro, Karolinska University Hospital, Stockholm, Sweden
PhDPhilip Sarajlic
1Department of Medicine, Karolinska Institutet, Theme Heart, Vessels, and Neuro, Karolinska University Hospital, Stockholm, Sweden
MDAlessandro Quaranta
2Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
PhDJohan Kolmert
2Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
3The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
PhDDorota Religa
4Department of Neurobiology, Karolinska Institutet and Theme Ageing, Karolinska University Hospital, Stockholm, Sweden
MD PhDCraig E. Wheelock
2Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
5Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden
PhDMagnus Bäck
1Department of Medicine, Karolinska Institutet, Theme Heart, Vessels, and Neuro, Karolinska University Hospital, Stockholm, Sweden
MD PhDData Availability
Individual participant data that underlie the results reported will be shared, after deidentification, with researchers who provide a methodologically sound proposal. Time Frame: Beginning 9 months following article publication and finishing 36 months following article publication. Access Criteria: Investigators interested in data should contact the corresponding author.
Posted December 31, 2021.
Immunomodulation by intravenous omega-3 fatty acid treatment in older subjects hospitalized for COVID-19: a single-blind randomized controlled trial
Hildur Arnardottir, Sven-Christian Pawelzik, Philip Sarajlic, Alessandro Quaranta, Johan Kolmert, Dorota Religa, Craig E. Wheelock, Magnus Bäck
medRxiv 2021.12.27.21268264; doi: https://doi.org/10.1101/2021.12.27.21268264
Immunomodulation by intravenous omega-3 fatty acid treatment in older subjects hospitalized for COVID-19: a single-blind randomized controlled trial
Hildur Arnardottir, Sven-Christian Pawelzik, Philip Sarajlic, Alessandro Quaranta, Johan Kolmert, Dorota Religa, Craig E. Wheelock, Magnus Bäck
medRxiv 2021.12.27.21268264; doi: https://doi.org/10.1101/2021.12.27.21268264
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2657)
- Dermatology (224)
- Emergency Medicine (401)
- Epidemiology (12254)
- Forensic Medicine (10)
- Gastroenterology (765)
- Genetic and Genomic Medicine (4116)
- Geriatric Medicine (387)
- Health Economics (681)
- Health Informatics (2666)
- Health Policy (1007)
- Hematology (364)
- HIV/AIDS (854)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (440)
- Neurology (3899)
- Nursing (210)
- Nutrition (579)
- Oncology (2038)
- Ophthalmology (586)
- Orthopedics (242)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (452)
- Public and Global Health (6542)
- Radiology and Imaging (1407)
- Respiratory Medicine (871)
- Rheumatology (411)
- Sports Medicine (343)
- Surgery (452)
- Toxicology (54)
- Transplantation (185)
- Urology (166)